Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBPP) Other Non Operating Income (2017 - 2025)

Regen BioPharma (RGBPP) has disclosed Other Non Operating Income for 9 consecutive years, with -$299216.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income fell 7712.43% to -$299216.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$675528.0, a 16412.54% decrease, with the full-year FY2025 number at -$675528.0, down 16412.54% from a year prior.
  • Other Non Operating Income was -$299216.0 for Q3 2025 at Regen BioPharma, down from -$89259.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $70.1 million in Q3 2022 to a low of -$66.6 million in Q1 2022.
  • A 5-year average of -$261026.6 and a median of -$46544.5 in 2024 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: soared 287484.58% in 2022, then crashed 34098.85% in 2025.
  • Regen BioPharma's Other Non Operating Income stood at -$95019.0 in 2021, then skyrocketed by 2326.72% to $2.1 million in 2022, then crashed by 199.95% to -$2.1 million in 2023, then surged by 80.33% to -$416016.0 in 2024, then increased by 28.08% to -$299216.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Other Non Operating Income are -$299216.0 (Q3 2025), -$89259.0 (Q2 2025), and $128963.0 (Q1 2025).